GSK asks for results from Exelixis cancer drug

08/23/2007 | Bloomberg

GlaxoSmithKline has requested preliminary study results from Exelixis for the experimental cancer drug XL880. Exelixis could receive a $70 million milestone payment if GSK continues to develop the drug, one analyst said.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Director of Program Development
AdvaMed
Washington DC, DC
Director of System QA
LifeWatch Services, Inc.
Rosemont, IL
Director of Business Development and Membership
AdvaMed
Washington DC, DC
Director, Corporate Counsel
Regeneron
Tarrytown, NY